Headlines & Media Coverage
What the press is saying about ABILITY Neurotech and our work in brain-computer interfaces.
Recent Headlines & Media Mentions
Jun 30, 2026 Ascending BCI systems deepen national security, ethical concerns
As brain-computer interface technology advances rapidly, new questions arise about dual-use implications, data sovereignty, and the ethical frameworks needed to govern neural devices.
Jun 23, 2026 Next wave of BCI firms builds on pioneers to tackle challenges
A new generation of brain-computer interface companies, including ABILITY Neurotech, is building on early pioneers to address the technical and regulatory hurdles that remain before BCIs can reach broad clinical use.
Jun 23, 2026 Neurotechnologies: Comment Genève tente d'exister face à la Silicon Valley
Geneva positions itself as a European hub for neurotechnology, with companies like ABILITY Neurotech emerging from the Wyss Center to compete on the global stage against Silicon Valley giants.
Jun 16, 2026 ABILITY Neurotech receives approval to start clinical trial
The Swiss-based brain-computer interface company has received regulatory approval in the Netherlands to begin its first chronic implantation study in ALS patients.
Jun 9, 2026 Optical brain implant moves into real-world use
ABILITY Neurotech's fully implantable BCI, featuring a 50 Mb/s transcutaneous optical data link, is moving from the lab into real-world clinical evaluation for restoring speech in paralysed patients.
May 28, 2026 ABILITY Neurotech: Unlocking the Potential of BCI
An in-depth feature exploring ABILITY Neurotech's approach to brain-computer interfaces, its optical-link technology, and the company's path toward clinical deployment for speech restoration.
May 28, 2026 Ability Neurotech can begin study of BCI in ALS patients
ABILITY Neurotech has secured IMDD approval to launch its first chronic implantation study of a fully implantable wireless brain-computer interface in ALS patients at UMC Utrecht.
May 28, 2026 ABILITY Neurotech gets approval to trial brain-computer interface in ALS patients
The clinical-stage BCI company has received ethics committee approval to trial its fully implantable device designed to restore communication for people living with ALS.
May 28, 2026 ABILITY Neurotech receives MREC approval for ALS BCI clinical trial
ABILITY Neurotech has received Medical Research Ethics Committee approval in the Netherlands for its first chronic implantation clinical trial of an ECoG-based brain-computer interface.
Media Inquiries
For press inquiries, interview requests, or media resources, please get in touch with our communications team.
Contact Us